ACB

Aurora Cannabis Inc. (ACB) | Rumor.io

Aurora Cannabis

ACB

Attention (50-day avg)0.01%

Attention rank (50-day avg)#398

Bullish sentiment (50-day avg)70%

Price to earnings ratio20.8

Market capitalization258.9M

Earnings per share-0.65

Dividend yield (TTM)—

Revenue (annual)320.6M

Net income (annual)-136M

Social

What share of all stock conversation is about ACB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% -0.01	0.01% 0	0% -0.01

Sep 24

Aurora Cannabis has filed an application with the Alberta Securities Commission to protect shareholders from deficiencies in Curaleaf's hostile bid disclosure.
Some shareholders are urging management to do a valuation on their own assets to support their worth, while others are outraged by the company's lack of care for shareholder value.
The potential takeover by Curaleaf could result in a significant drop in stock price if it's rejected, and some analysts believe that a fair price for Aurora would be around $3-$4 per share.

Generated by AI

Sentiment

Of the messages about ACB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	77.42% -5.22	55.69% -23.77	87.63% -2.36
Bearish	0% 0	22.58% +5.22	44.31% +23.77	12.37% +2.36

Bullish· Aug 12

$ACB has a strong cash position with $150 million in cash and a manageable 56 million shares outstanding, which could support future growth and M&A activity.
Aurora's medical cannabis platform is unmatched, with a unique opportunity for consolidation and potential M&A deals with other companies in the industry.
$ACB is poised to reach $10-$12 per share, with some analysts suggesting an offer price of $5.75 and others predicting a target price of $100.

Bearish· Aug 11

The company's offer to acquire Curaleaf for $4 per share is considered too low, with one user stating that the stock is worth at least $4 per share, and another claiming it's worth more than $6 per share.
The company has a significant amount of debt, with one user pointing out that it has $500 million in debt and 259 million shares outstanding, making the offer even more questionable.
The deal is seen as a low-ball offer, with one user stating that the company is "purposely said that they were going to have low guidance last ER because they knew this deal was coming", suggesting that the deal was pre-planned to artificially lower the stock price.

Generated by AI

Topics

Of the messages about ACB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	28.33%	79.83%	70.52%
Technical Analysis	100%	0.68%	2.09%	5.67%
Controversies	0%	25.26%	7.44%	3.78%
Macro	0%	23.55%	5.77%	11.44%
Earnings	0%	0%	0.35%	3.98%
Analysts	0%	22.18%	4.52%	4.62%

Earnings· Nov 5

Aurora Cannabis reports Q2 2026 results with $90.4 million in revenue, an 11% year-over-year increase, and a net loss of $53.2 million.
The company's medical cannabis segment saw a 15% year-over-year increase in revenue, accounting for 78% of total net revenue and 94% of adjusted gross profit.
Aurora Cannabis missed earnings expectations, with an adjusted EPS of $(0.19), but beat revenue expectations with $65.64 million in sales, a 10.38% year-over-year increase.

Analysts· May 14

BMO Capital Markets upgraded Aurora Cannabis to Market Perform, lowering the price target to C$8 from C$9.
Canaccord Genuity downgraded Aurora Cannabis to Sell, setting a price target of C$7.
ATB Capital Markets downgraded Aurora Cannabis to Underperform, setting a price target of C$7.50.

Announcements· Aug 24

Aurora Cannabis has rejected Curaleaf's hostile takeover bid, calling it opportunistic and pointing out inaccuracies in Curaleaf's portrayal of their business.
Curaleaf has responded to Aurora's statements, calling them "hollow protests" and "completely misleading", and asserting that Aurora's characterization of their engagement is "misleading".
Aurora's management has highlighted the inaccuracies in Curaleaf's takeover bid announcement, claiming that their business is reaching a pivotal inflection point and that Curaleaf's offer undervalues the company.

Controversies· Nov 18

Multiple law firms are investigating claims against Aurora Cannabis Inc. ($ACB) and encouraging investors with losses to contact them.
Investors are expressing skepticism about the legitimacy of these lawsuits, comparing them to "ambulance chasing lawyers" and "low tier lawyers looking for a buck".
The lawsuits are reportedly in response to Aurora Cannabis Inc.'s recent financial performance, including a significant decline in stock price.

Technical Analysis· Feb 6

ACB has confirmed an hourly bull flag, with a target price of $8.01 USD.
The stock's performance is attributed to a potential Daily 2 High Volume Crossover (HVC) move above the $5 whole number.
ACB's chart is showing signs of overbought conditions, with a likely pullback to the 200 SMA at $5.49 to test support.

Generated by AI

Community

Of the messages about ACB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	70.59%	55.22%	46.42%	62.36%
Newcomers	29.41%	44.78%	53.58%	37.64%

Regulars· Sep 22

Regulars are discussing the potential for a deal between Aurora Cannabis (ACB) and Curaleaf (CURLF) to be completed, which could impact ACB's stock price.
Some regulars believe that ACB's stock price will drop by 50% if the deal with CURLF is not completed, while others think that ACB's price is already linked to CURLF's offer price and will reach $5.
The regulars are also discussing the potential for ACB to be undervalued, with some thinking that the current offer price is "on the cheap" and others believing that the company will do fine on its own without a deal with CURLF.

Newcomers· Aug 24

The company's valuation and turnaround strategy are being questioned by some investors, who claim that its value does not reflect its promised results.
Aurora Cannabis is facing a hostile bid from Curaleaf, and a special committee is reviewing the offer, with a market capitalization of $172M and an enterprise value of $106M.
Some traders are using Elliott Wave analysis to predict a potential major wave up in the stock's price, which could lead to a significant increase in value, possibly exceeding $5 per share.

Generated by AI

News

Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch. | The Motley Fool

Hostile takeovers are called hostile for a reason, and this one is getting ugly.

4d agoThe Motley Fool

Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure

Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.

6d agoThe Globe and Mail

Also Discussed

Investors talking about ACB also mention

#	Name	Attention
1	Canopy Growth CorporationCGC	0%-0.01
2	HEXO - HEXO Corp.	——
3	Cronos Group Inc.CRON	0%+0
4	Tilray Brands Inc.TLRY	0.02%0
5	Organigram Global Inc.OGI	0.01%new
6	Village Farms International Inc.VFF	0.01%-0.01
7	Amphenol CorpAPH	0%+0
8	Amplify Alternative Harvest ETFMJ	0%new
9	TrustCo Bank Corp. NYTRST	0%new
10	AdvisorShares Pure US Cannabis ETFMSOS	0.49%-0.18

Aurora Cannabis Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Aurora Cannabis Inc. is a Canadian cannabis company focused on the production, distribution, and sale of cannabis and cannabis-derived products in Canada and international markets. Aurora Cannabis Inc. serves both medical and consumer segments with offerings that include pharmaceutical-grade cannabis, dried flower, oils, capsules, concentrates, and other product formats designed for adult-use and therapeutic applications. The company operates through cannabis and plant propagation businesses, supporting a portfolio that spans branded consumer products, medical cannabis channels, and agricultural propagation activities. Headquartered in Edmonton, Alberta, Aurora Cannabis Inc. plays a notable role in the regulated cannabis industry by supplying patients, consumers, and wholesale partners across multiple regions.

Website

Location

90B Street SW

Edmonton, AB, T6X 1V8

Canada

Social

What share of all stock conversation is about ACB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% -0.01	0.01% 0	0% -0.01

Sep 24

Aurora Cannabis has filed an application with the Alberta Securities Commission to protect shareholders from deficiencies in Curaleaf's hostile bid disclosure.
Some shareholders are urging management to do a valuation on their own assets to support their worth, while others are outraged by the company's lack of care for shareholder value.
The potential takeover by Curaleaf could result in a significant drop in stock price if it's rejected, and some analysts believe that a fair price for Aurora would be around $3-$4 per share.

Generated by AI

Sentiment

Of the messages about ACB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	77.42% -5.22	55.69% -23.77	87.63% -2.36
Bearish	0% 0	22.58% +5.22	44.31% +23.77	12.37% +2.36

Bullish· Aug 12

$ACB has a strong cash position with $150 million in cash and a manageable 56 million shares outstanding, which could support future growth and M&A activity.
Aurora's medical cannabis platform is unmatched, with a unique opportunity for consolidation and potential M&A deals with other companies in the industry.
$ACB is poised to reach $10-$12 per share, with some analysts suggesting an offer price of $5.75 and others predicting a target price of $100.

Bearish· Aug 11

The company's offer to acquire Curaleaf for $4 per share is considered too low, with one user stating that the stock is worth at least $4 per share, and another claiming it's worth more than $6 per share.
The company has a significant amount of debt, with one user pointing out that it has $500 million in debt and 259 million shares outstanding, making the offer even more questionable.
The deal is seen as a low-ball offer, with one user stating that the company is "purposely said that they were going to have low guidance last ER because they knew this deal was coming", suggesting that the deal was pre-planned to artificially lower the stock price.

Generated by AI

Topics

Of the messages about ACB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	28.33%	79.83%	70.52%
Technical Analysis	100%	0.68%	2.09%	5.67%
Controversies	0%	25.26%	7.44%	3.78%
Macro	0%	23.55%	5.77%	11.44%
Earnings	0%	0%	0.35%	3.98%
Analysts	0%	22.18%	4.52%	4.62%

Earnings· Nov 5

Aurora Cannabis reports Q2 2026 results with $90.4 million in revenue, an 11% year-over-year increase, and a net loss of $53.2 million.
The company's medical cannabis segment saw a 15% year-over-year increase in revenue, accounting for 78% of total net revenue and 94% of adjusted gross profit.
Aurora Cannabis missed earnings expectations, with an adjusted EPS of $(0.19), but beat revenue expectations with $65.64 million in sales, a 10.38% year-over-year increase.

Analysts· May 14

BMO Capital Markets upgraded Aurora Cannabis to Market Perform, lowering the price target to C$8 from C$9.
Canaccord Genuity downgraded Aurora Cannabis to Sell, setting a price target of C$7.
ATB Capital Markets downgraded Aurora Cannabis to Underperform, setting a price target of C$7.50.

Announcements· Aug 24

Aurora Cannabis has rejected Curaleaf's hostile takeover bid, calling it opportunistic and pointing out inaccuracies in Curaleaf's portrayal of their business.
Curaleaf has responded to Aurora's statements, calling them "hollow protests" and "completely misleading", and asserting that Aurora's characterization of their engagement is "misleading".
Aurora's management has highlighted the inaccuracies in Curaleaf's takeover bid announcement, claiming that their business is reaching a pivotal inflection point and that Curaleaf's offer undervalues the company.

Controversies· Nov 18

Multiple law firms are investigating claims against Aurora Cannabis Inc. ($ACB) and encouraging investors with losses to contact them.
Investors are expressing skepticism about the legitimacy of these lawsuits, comparing them to "ambulance chasing lawyers" and "low tier lawyers looking for a buck".
The lawsuits are reportedly in response to Aurora Cannabis Inc.'s recent financial performance, including a significant decline in stock price.

Technical Analysis· Feb 6

ACB has confirmed an hourly bull flag, with a target price of $8.01 USD.
The stock's performance is attributed to a potential Daily 2 High Volume Crossover (HVC) move above the $5 whole number.
ACB's chart is showing signs of overbought conditions, with a likely pullback to the 200 SMA at $5.49 to test support.

Generated by AI

Community

Of the messages about ACB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	70.59%	55.22%	46.42%	62.36%
Newcomers	29.41%	44.78%	53.58%	37.64%

Regulars· Sep 22

Regulars are discussing the potential for a deal between Aurora Cannabis (ACB) and Curaleaf (CURLF) to be completed, which could impact ACB's stock price.
Some regulars believe that ACB's stock price will drop by 50% if the deal with CURLF is not completed, while others think that ACB's price is already linked to CURLF's offer price and will reach $5.
The regulars are also discussing the potential for ACB to be undervalued, with some thinking that the current offer price is "on the cheap" and others believing that the company will do fine on its own without a deal with CURLF.

Newcomers· Aug 24

The company's valuation and turnaround strategy are being questioned by some investors, who claim that its value does not reflect its promised results.
Aurora Cannabis is facing a hostile bid from Curaleaf, and a special committee is reviewing the offer, with a market capitalization of $172M and an enterprise value of $106M.
Some traders are using Elliott Wave analysis to predict a potential major wave up in the stock's price, which could lead to a significant increase in value, possibly exceeding $5 per share.

Generated by AI

Aurora Cannabis

Social

Sep 24

Bullish· Aug 12

Bearish· Aug 11

Earnings· Nov 5

Analysts· May 14

Announcements· Aug 24

Controversies· Nov 18

Technical Analysis· Feb 6

Regulars· Sep 22

Newcomers· Aug 24

Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch. | The Motley Fool

Aurora Cannabis Inc. stock falls Friday, underperforms market

Aurora And Curaleaf’s Hostile Bid Fight Gets Even Messier

Aurora Cannabis Inc. stock falls Thursday, underperforms market

Aurora Cannabis files complaint over Curaleaf takeover bid

Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure

Also Discussed

Aurora Cannabis Inc.

Company Information

Location

Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch. | The Motley Fool

Aurora Cannabis Inc. stock falls Friday, underperforms market

Aurora And Curaleaf’s Hostile Bid Fight Gets Even Messier

Aurora Cannabis Inc. stock falls Thursday, underperforms market

Aurora Cannabis files complaint over Curaleaf takeover bid

Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure

Also Discussed

Social

Sep 24

Bullish· Aug 12

Bearish· Aug 11

Earnings· Nov 5

Analysts· May 14

Announcements· Aug 24

Controversies· Nov 18

Technical Analysis· Feb 6

Regulars· Sep 22

Newcomers· Aug 24